Search Results - "Ginba, Hiroyuki"

Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients by Tsuge, Masataka, Murakami, Eisuke, Imamura, Michio, Abe, Hiromi, Miki, Daiki, Hiraga, Nobuhiko, Takahashi, Shoichi, Ochi, Hidenori, Nelson Hayes, C., Ginba, Hiroyuki, Matsuyama, Kazuhiro, Kawakami, Hiroiku, Chayama, Kazuaki

“…Background Treatment for chronic hepatitis B has improved drastically with the use of nucleot(s)ide analogues (NAs). However, NA therapy typically fails to…”
Get full text

Evaluation of pathogen detection from clinical samples by real-time polymerase chain reaction using a sepsis pathogen DNA detection kit by Yanagihara, Katsunori, Kitagawa, Yuko, Tomonaga, Masao, Tsukasaki, Kunihiro, Kohno, Shigeru, Seki, Masafumi, Sugimoto, Hisashi, Shimazu, Takeshi, Tasaki, Osamu, Matsushima, Asako, Ikeda, Yasuo, Okamoto, Shinichiro, Aikawa, Naoki, Hori, Shingo, Obara, Hideaki, Ishizaka, Akitoshi, Hasegawa, Naoki, Takeda, Junzo, Kamihira, Shimeru, Sugahara, Kazuyuki, Asari, Seishi, Murata, Mitsuru, Kobayashi, Yoshio, Ginba, Hiroyuki, Sumiyama, Yoshinobu, Kitajima, Masaki

“…Sepsis is a serious medical condition that requires rapidly administered, appropriate antibiotic treatment. Conventional methods take three or more days for…”
Get full text

The role of a real-time PCR technology for rapid detection and identification of bacterial and fungal pathogens in whole-blood samples by Obara, Hideaki, Tanabe, Minoru, Kitajima, Masaki, Kitagawa, Yuko, Aikawa, Naoki, Hori, Shingo, Hasegawa, Naoki, Ikeda, Yasuo, Okamoto, Shinichiro, Kobayashi, Yoshio, Murata, Mitsuru, Takeda, Junzo, Sakakura, Yasuhiko, Ginba, Hiroyuki

“…Abstract The rapid diagnosis of pathogens and prompt initiation of appropriate antibiotic therapy are critical factors to reduce the morbidity and mortality…”
Get full text

Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin by Toyoda, Hidenori, Kumada, Takashi, Shimada, Noritomo, Takaguchi, Koichi, Ide, Tatsuya, Sata, Michio, Ginba, Hiroyuki, Matsuyama, Kazuhiro, Izumi, Namiki

“…The importance of the reduction in hepatitis C virus (HCV) RNA levels 4 and 12 weeks after starting peginterferon (PEG-IFN) and ribavirin combination therapy…”
Get full text

Identification of the DNA binding surface of H-NS protein from Escherichia coli by heteronuclear NMR spectroscopy by Shindo, Heisaburo, Ohnuki, Ayumi, Ginba, Hiroyuki, Katoh, Etsuko, Ueguchi, Chiharu, Mizuno, Takeshi, Yamazaki, Toshimasa

“…The DNA binding domain of H-NS protein was studied with various N-terminal deletion mutant proteins and identified by gel retardation assay and heteronuclear…”
Get full text

Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: A multicenter study by Toyoda, Hidenori, Kumada, Takashi, Shimada, Noritomo, Takaguchi, Koichi, Ide, Tatsuya, Sata, Michio, Ginba, Hiroyuki, Matsuyama, Kazuhiro, Izumi, Namiki

“…Both baseline predictive factors and viral response at week 4 of therapy are reported to have high predictive ability for sustained virologic response to…”
Get full text

Characteristics and outcomes of HCV genotype-1-infected patients treated with peginterferon and ribavirin combination therapy with discordant HCV responses 4 and 12 weeks after starting therapy by Toyoda, Hidenori, Kumada, Takashi, Shimada, Noritomo, Takaguchi, Koichi, Ide, Tatsuya, Sata, Michio, Ginba, Hiroyuki, Matsuyama, Kazuhiro, Izumi, Namiki

“…Some patients with chronic hepatitis C virus (HCV) infection fail to achieve complete early virologic response (EVR) despite a marked decrease in HCV RNA at 4…”
Get more information